MPI Research today announced that several of its key staff members have achieved recent notable designations and certifications, adding to depth of distinguished professionals working for the company. The achievements range from Diplomat certifications for the American Board of Toxicology (DABT) and the Safety Pharmacology Society (DSP), as well as the completion of two Ph.Ds.
“It is always an honor to have dedicated staff tirelessly working to increase their knowledge base and expand their professional skills,” said William U. Parfet, MPI Research Chairman and CEO. “At MPI Research, we fully support our staff members continuing their education and taking an active role in our industry. This approach fosters our growth as an organization and ultimately improves the service we can provide our Sponsors.”
Dr. Melissa Peet and Dr. Matthew Abernathy both earned their Ph.D. from Western Michigan University. Dr. Peet, a Senior Study Director at MPI Research, received her Ph.D. in behavior analysis and has authored several peer-reviewed journal articles and posters in the field of behavioral pharmacology and toxicology. Dr. Abernathy, a Study Director in the Neurobehavioral Sciences department, earned his Ph.D. in biological sciences. He previously served as a surgical research technician for Borgess Research Institute.
Three employees received their Diplomacy to the Board of Toxicology: Zac Lloyd, Senior Study Director in General Toxicology, Daniel Patrick, Director of Pathology, and Dr. Chidozie Amuzie, Principal Pathologist. Lloyd has been with MPI Research since 1998 and has conducted various GLP toxicology studies, acting as a Project Leader and Group Leader in Small Animal Toxicology. Patrick has authored several textbook chapters on pathology, is an adjunct professor at Michigan State University, and holds a variety of memberships to professional organizations including American College of Toxicology and the Society of Toxicology. Dr. Amuzie received his Ph.D. from Michigan State University in comparative medicine and environmental toxicology, and has published and peer-reviewed several articles in toxicology, pathology and other life science journals.
Marci Harter, Study Director, recently became a Diplomat to Safety Pharmacology Society and has more than 10 years of experience at MPI Research. She is an expert in the field of development, conduct, data interpretation and reporting of preclinical safety pharmacology and toxicology studies. Harter has authored several presentations and posters and received her bachelor of science in biomedical sciences.
The achievements of these individuals showcase their dedication to MPI Research, their Sponsors and the advancement of scientific discovery.
About MPI Research
MPI Research, with global headquarters in Mattawan, Michigan, provides safety evaluation, discovery, bioanalytical, and analytical – and now phase I clinical – services to the biopharmaceutical, medical device, animal health, and chemical industries. The company also offers comprehensive imaging solutions including preclinical and clinical imaging, radiochemistry, and data analysis. Scientific knowledge and experience, responsiveness, integrity, trust, teamwork, and dedication to strong and enduring Sponsor relationships are the defining attributes that characterize MPI Research as a high-performance, high-quality organization that is committed to bringing safer and more effective products to the world. Learn more about how we can exceed your expectations at www.mpiresearch.com.